Breast cancer prognostic factors/pathobiology

乳腺癌预后因素/病理学

基本信息

批准号：
7933190
负责人：
KATHLEEN E MALONE
金额：
$ 17.44万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2011-03-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7933190
关键词：
Address Affect Age Age-Years Aging Ancillary Study Biology Blood Body Size Body Weight Changes Breast Cancer Prognostic Factor Cancer Etiology Cell Cycle Proteins Cessation of life Characteristics Clinical Clinical Trials Cohort Studies Cyclin D1 Cyclin E DNA Data Diagnosis Diagnostic Disease Progression Enrollment Family history of Follow-Up Studies Foundations Future Goals Grant Hormones Incidence Interview Investigation Medical Records Molecular Pathology Patients Persons Pharmaceutical Preparations Phase Physical activity Ploidies Population Prognostic Marker Recurrence Reproductive History Resources Risk Risk Factors Staging TP53 gene Telephone Interviews Testing Time Tissue Microarray Tissues Tumor Markers Woman age group aged base breast cancer diagnosis cohort disease diagnosis flexibility follow-up insight malignant breast neoplasm mortality novel marker older women outcome forecast population based response tumor tumor progression

项目摘要

DESCRIPTION (provided by applicant): Breast cancer mortality is the second leading cause of cancer death in women. In spite of improvements in stage and advances in treatment, mortality from breast cancer continues to be substantial and there exists a paucity of insights regarding factors that influence disease progression and mortality. In particular, little is known about how patient and tumor characteristics relate to mortality in middle- and older aged women. We propose to conduct a population-based molecular-epidemiologic cohort study of factors that predict mortality in women diagnosed with invasive breast cancer at ages 45 through 79. The overall goal of the study is to evaluate patient and tumor characteristics for their relationship with the risk of breast cancer mortality. The proposed cohort consists of 2337 women diagnosed with a first invasive breast cancer at 45-79 years of age during the period 1993-1999, all of whom previously completed an extensive interview regarding exposures prior to diagnosis and will now be followed for mortality. Telephone interviews and medical record reviews will be used to collect information on exposures after diagnosis, disease recurrences, and treatment details. Tumor characteristics and markers will be assessed in relation to both mortality and patient factors as a basis for understanding determinants of prognosis. The aims of this study are: (1) to determine if patient characteristics and exposures (before and after diagnosis), including some which are potentially modifiable, are related to the risk of dying from breast cancer, (2) to determine if patient characteristics and exposures prior to diagnosis are associated with histopathologic features and tumor markers, (3) to assess the relationship of histopathologic factors and tumor markers, including both well characterized prognostic markers and less well-characterized cell cycle proteins, with the risk of dying from breast cancer, (4) to build tissue microarrays that will allow rapid assessment of future markers as they are identified, (5) to build a comprehensive resource for future ancillary studies. The investigation of tumor and patient characteristics in relation to mortality could provide etiologic and clinical insights regarding determinants of prognosis and help to generate clues regarding the biology of breast cancer progression.

描述（由申请人提供）：乳腺癌死亡率是女性癌症死亡的第二大原因。尽管阶段的改善和治疗的进步，乳腺癌的死亡率仍然很高，并且对影响疾病进展和死亡率的因素缺乏了解。特别是，人们对患者和肿瘤特征与中老年女性死亡率的关系知之甚少。我们建议开展一项基于人群的分子流行病学队列研究，研究预测 45 至 79 岁诊断为浸润性乳腺癌女性死亡率的因素。该研究的总体目标是评估患者和肿瘤特征与风险的关系。乳腺癌的死亡。拟议的队列由 2337 名在 1993 年至 1999 年期间在 45-79 岁期间首次诊断出患有浸润性乳腺癌的女性组成，所有这些女性在诊断前都完成了有关暴露的广泛访谈，现在将跟踪死亡率。电话访谈和病历审查将用于收集诊断后的暴露信息、疾病复发和治疗细节。将根据死亡率和患者因素评估肿瘤特征和标志物，作为了解预后决定因素的基础。本研究的目的是：(1) 确定患者特征和暴露（诊断前后）（包括一些可能可改变的）是否与死于乳腺癌的风险相关，(2) 确定患者特征和暴露是否与乳腺癌死亡风险相关诊断前的暴露与组织病理学特征和肿瘤标志物相关，(3) 评估组织病理学因素和肿瘤标志物的关系，包括明确表征的预后标志物和不太明确表征的细胞周期蛋白与乳腺癌死亡风险的关系癌症，(4) 构建组织微阵列，以便快速评估未来标记物的识别，(5) 为未来的辅助研究建立全面的资源。对与死亡率相关的肿瘤和患者特征的研究可以提供有关预后决定因素的病因学和临床见解，并有助于产生有关乳腺癌进展的生物学线索。